← SynDRA
SELONSERTIB
SynDRA canonical compound SYN0038637 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Primary target(s) | MAP3K5 |
|---|
| Mechanism of action | MAP kinase activator |
|---|
All known targets
Mechanisms of action (all sources)
- MAP3K5 INHIBITOR
- Mitogen-activated protein kinase kinase kinase 5 inhibitor
- MAP kinase activator
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- MAP3K6
- SYK
- PRKD2
- PTK2
- PRP4K
- PRKX
- PRKG2
- PRKG1
- PRKD3
- CDC42BPA
- RAF1
- PRKD1
- PRKCQ
- PRKCI
- PRKCH
- PRKCE
- PRKCD
- PTK2B
- RET
- PRKACA
- RIOK1
- RIOK2
- RIOK3
- RIPK1
- RIPK2
- RIPK4
- ROCK1
- ROCK2
- ROS1
- RPS6KA1
- RPS6KA2
- RPS6KA3
- RPS6KA4
- RPS6KA5
- PRKACB
- PLK4
- RPS6KB1
- PDGFRB
- PIK3C2G
- PIK3C2B
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Drug classes
- Protein Kinase Inhibitors
Cross-references
Synonyms
- GS-4997
- GS 4997
- NS3988A2TC
- selonsertibum
- RefChem:884861
- Selonsertib [INN]
- Selonsertib(GS-4997)
- C24H24FN7O
- MFCD29920355
- Selonsertib (GS-4997)
- UNII-NS3988A2TC
- NJV
- SelonsertibGS-4997
- SelonsertibGS-4997?
- SELONSERTIB [JAN]
- GS-4997; Selonsertib
- Selonsertib [USAN:INN]
- Selonsertib; GS-4997
- SELONSERTIB [USAN]
- SELONSERTIB [WHO-DD]
- Selonsertib (JAN/USAN/INN)
- GTPL9040
- orb1304295
- SCHEMBL14672984
- SCHEMBL29977277
- YIDDLAAKOYYGJG-UHFFFAOYSA-N
- GLXC-10333
- EX-A1150
- EX-A1618
- BDBM50212258
- GS4997
- NSC797772
- s8292
- AKOS027338646
- CCG-269184
- CS-5328
- EBC-222024
- NSC-797772
- SB17466
Look up SELONSERTIB in the interactive SynDRA portal →